Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
← catalyst calendarNCT06526793 · readout in 610 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
270estimated
Sites
94
Countries
Australia, Brazil, Canada +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-27 | actual | When the study began enrolling |
| Primary completion | 2028-04-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-10-21 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- B-cell Non-Hodgkin Lymphoma
- Follicular Lymphoma (FL)
- Large B-Cell Lymphoma (LBCL)
Intervention
- Drug: Surovatamig — also filed as AZD0486
Primary outcome
what the primary-completion date above is the date OFOverall response rate (ORR) (central review)
measured Module 1: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to approximately 24 months. Module 2: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to approximately 12 months.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed